New Link Found in Lung Cancer
Researchers studied a type of protein modification called myristoylation in non-small cell lung cancer cells. They found that certain proteins, including GLIPR2, play a role in a process called ferroptosis, which can kill cancer cells. The researchers used a new method to identify these proteins and understand their function.
Why it matters: This finding could lead to new therapeutic strategies for non-small cell lung cancer.
This is an early stage, preclinical study.
View source →Trial Tests New Drug for Metastatic Cancers
This trial is studying the addition of a new anti-cancer drug, ZEN003694, to the usual chemotherapy treatment for metastatic or unresectable cancers. The trial is currently recruiting participants. It's too early to know if this combination will be effective.
Why it matters: This trial matters because it may lead to new treatment options for people with metastatic or unresectable cancers.
The trial is in its early stage and still recruiting participants, so limited data is available.
View source →Lung Cancer Treatment Study
This trial is studying how well chemotherapy and immunotherapy work in patients with non-small cell lung cancer. The trial is currently recruiting participants and aims to compare treatment outcomes in patients with different levels of physical ability. It's still unclear what the results will show.
Why it matters: This trial matters because it may help doctors understand how to better treat lung cancer patients with varying levels of physical ability.
The trial is currently recruiting and is in an early stage, so limited data is available.
View source →Prostate Cancer Treatment Study
This trial is studying bicalutamide with or without an Akt inhibitor for previously treated prostate cancer. The trial is currently active but not recruiting new patients. Researchers are exploring the effectiveness of this combination.
Why it matters: This trial matters because it may help find new ways to treat prostate cancer that has been previously treated.
The trial is currently not recruiting new patients and is in an early stage of research.
View source →M1774 for Refractory Prostate Cancer
This trial is studying the effect of M1774 on a type of hard-to-treat prostate cancer. The trial is currently active but not recruiting new participants. Researchers are using various tests to evaluate the treatment's effects.
Why it matters: This trial matters because it may help find new treatments for patients with refractory prostate cancer that has not responded to other therapies.
The trial is currently not recruiting new participants and is in an early stage of research.
View source →Trial of ESK981 for Solid Tumors
This trial is studying the effects of ESK981 in patients with certain types of solid tumors. The trial is currently recruiting participants. It's too early to know if ESK981 will be effective for these conditions.
Why it matters: This trial matters because it may help find new treatments for patients with select solid tumors.
The trial is currently recruiting and is in an early stage, so limited data is available.
View source →Prostate Cancer Treatment Trial
This trial is studying treatments for advanced prostate cancer that has not responded to hormonal therapy. It is comparing different combinations of medications, including radiation and immunotherapy. The trial is currently recruiting participants.
Why it matters: This trial matters because it may help find new and more effective treatments for advanced prostate cancer.
The trial is in its early stage and currently recruiting participants, so limited data is available.
View source →Prostate Cancer Radiation Treatment Trial
This trial is studying the safety and effectiveness of a radiation-based treatment for metastatic prostate cancer with neuroendocrine cells. The trial is currently recruiting participants. The treatment being tested is Lutetium Lu 177 Dotatate.
Why it matters: This trial matters because it may help find a new treatment option for patients with metastatic prostate cancer that has neuroendocrine cells.
The trial is in its early stages and is still recruiting participants, so limited data is available.
View source →Lung Cancer Treatment Trial
This trial is studying the addition of immunotherapy to chemotherapy for non-small cell lung cancer. The trial is currently recruiting participants. It aims to find out if this combination is effective.
Why it matters: This trial matters because it may help find a new way to treat non-small cell lung cancer.
The trial is currently recruiting and no results are available yet.
View source →Trial for Metastatic Breast Cancer
This trial is studying a new combination of treatments for metastatic triple-negative breast cancer. It's adding an anti-cancer drug to chemotherapy and immunotherapy. The trial is currently recruiting participants.
Why it matters: This trial matters because it may help find new ways to treat metastatic triple-negative breast cancer, a condition with limited treatment options.
The trial is in its early stage and currently recruiting, so limited data is available.
View source →Tamoxifen Dose Trial for Breast Cancer
This trial is studying the best dose of tamoxifen to reduce breast cancer risk in premenopausal women. The trial is currently recruiting participants. Researchers will collect data to determine the most effective dose.
Why it matters: This trial matters because it may help find a way to reduce breast cancer risk in premenopausal women with certain breast conditions.
The trial is in its early stage and is currently recruiting participants, so limited data is available.
View source →Prostate Cancer Drug Trial
This trial is studying a new drug, AZD0516, for metastatic prostate cancer. It's looking at the drug alone and in combination with another drug, AZD9574. The trial is currently recruiting participants.
Why it matters: This trial matters because it could potentially lead to new treatment options for people with metastatic prostate cancer.
The trial is in its early stage and currently recruiting, so limited data is available.
View source →Talazoparib Trial for Advanced Cancer
This trial is studying the effects of talazoparib in patients with advanced cancer and DNA repair variations. The trial is currently recruiting participants. It aims to measure how well talazoparib works in these patients.
Why it matters: This trial matters because it may help determine if talazoparib is a useful treatment option for patients with advanced cancer and specific genetic characteristics.
The trial is currently recruiting and is in an early stage, so limited data is available.
View source →Genetic Testing for Cancer Treatment
This trial is studying how genetic testing can help guide targeted therapy for patients with advanced solid tumors. The trial is currently recruiting participants. It's unclear what the outcomes will be.
Why it matters: This trial matters because it may help find new ways to treat advanced cancers using targeted therapies based on genetic information.
The trial is currently recruiting and is in an early stage, so limited data is available.
View source →Immunotherapy for Rare Genitourinary Tumors
This trial is studying the effectiveness of two immunotherapy drugs and one anti-cancer targeted drug for rare genitourinary tumors. The trial is currently recruiting participants. It's too early to know if this treatment will be effective.
Why it matters: This trial matters because it may lead to new treatment options for people with rare and aggressive genitourinary tumors.
The trial is still recruiting and in an early stage, so limited data is available.
View source →Prostate Cancer Monitoring Trial
This trial is studying the use of 18F-DCFpyL to monitor prostate cancer that has come back after treatment. The trial is currently recruiting participants. It aims to learn more about how this method works for monitoring the disease.
Why it matters: This trial matters because it could help improve the way doctors monitor prostate cancer that has returned after treatment.
The trial is currently recruiting and the phase is not specified, indicating it is in an early stage with limited data available.
View source →Prostate Cancer Treatment Study
This trial is studying a treatment for metastatic castration-resistant prostate cancer. The study is currently recruiting participants with varying levels of kidney function. Researchers are looking at the effects of a specific treatment on this type of cancer.
Why it matters: This trial matters because it may help find new ways to treat prostate cancer that has spread and is resistant to standard hormone therapy.
The trial is in its early stage and is still recruiting participants, so limited data is available.
View source →Lung Cancer Treatment Study
This trial is studying a combination of two drugs, osimertinib and necitumumab, for patients with a type of lung cancer that has spread or come back. The trial is currently active but not recruiting new patients. Researchers are trying to learn if this treatment is safe and effective for these patients.
Why it matters: This trial matters because it may help find new treatment options for patients with lung cancer that has progressed despite previous treatment.
The trial is in its early stages and not recruiting new patients, so limited data is available.
View source →Lung Cancer Treatment Trial
This trial is studying the combination of a new anti-cancer drug, Iadademstat, with other anti-cancer drugs for small cell lung cancer. The trial is currently recruiting participants. It aims to find out if this combination improves outcomes for people with this type of cancer.
Why it matters: This trial matters because it may help find new and more effective treatments for small cell lung cancer.
The trial is in its early stage and recruiting participants, so limited data is available.
View source →Tamoxifen and Omega-3 for Breast Cancer Risk
This trial is studying whether low-dose tamoxifen with or without omega-3 fatty acids can reduce breast cancer risk. The trial is currently recruiting participants with certain breast conditions. It's unclear what the results will show.
Why it matters: This trial matters because it may help find new ways to reduce breast cancer risk in people with certain breast conditions.
The trial is currently recruiting and is in an early stage, so limited data is available.
View source →Hormone Therapy for Breast Cancer
This trial is studying hormone therapy with or without chemotherapy for women who have had surgery for node-negative breast cancer. The trial is currently active but not recruiting new participants. Researchers are still gathering information.
Why it matters: This trial matters because it may help determine the best treatment approach for women with certain types of breast cancer.
The trial is no longer recruiting new participants.
View source →Vaccine Trial for HER-2 Breast Cancer
This trial is studying a vaccine to prevent recurrence in patients with HER-2 positive breast cancer. The trial is currently active but not recruiting new participants. It's too early to know if the vaccine will be effective.
Why it matters: This trial matters because it could potentially lead to a new way to prevent breast cancer from coming back in people with HER-2 positive breast cancer.
The trial is in an early stage and not recruiting new participants.
View source →Immunotherapy for Stage II-III Breast Cancer
This trial is studying the addition of an immunotherapy drug, MEDI4736, to the usual chemotherapy treatment for stage II-III breast cancer. The trial is currently recruiting participants. It aims to explore the potential benefits of combining these treatments.
Why it matters: This trial matters because it may help determine if adding immunotherapy to chemotherapy improves outcomes for people with stage II-III breast cancer.
The trial is currently recruiting and no results are available yet.
View source →Genetic Testing Guides Cancer Treatment
This trial is studying how genetic testing can help guide treatment for patients with advanced cancers. The trial is currently active but not recruiting new patients. It's exploring whether targeted therapies can be effective for various types of cancer.
Why it matters: This trial matters because it could help determine if genetic testing can improve treatment outcomes for patients with advanced cancers.
The trial is not recruiting new patients and is still in an early stage.
View source →Trial Tests Two Anti-Cancer Drugs
This trial is studying the combination of two anti-cancer drugs, DS-8201a and AZD6738, for advanced solid tumors with the HER2 protein or gene. The trial is currently recruiting participants. It's too early to know if this treatment will be effective.
Why it matters: This trial matters because it could potentially lead to new treatment options for people with advanced solid tumors.
The trial is in its early stage and is still recruiting participants, so limited data is available.
View source →Prostate Cancer Vaccine Trial
This trial is studying a combination of a DNA vaccine and an anti-PD-1 monoclonal antibody for non-castrate recurrent oligometastatic prostate cancer. The trial is currently recruiting participants. It's too early to know if this treatment will be effective.
Why it matters: This trial matters because it explores a new potential treatment approach for a specific type of prostate cancer.
The trial is in its early stage and recruiting participants, so limited data is available.
View source →Vaccine Added to Treatment for Metastatic Breast Cancer
This trial is studying the addition of an individualized vaccine to a combination of treatments for metastatic triple negative breast cancer. The trial is currently recruiting participants. It's too early to know if this approach will be effective.
Why it matters: This trial matters because it could potentially lead to a new treatment option for patients with metastatic triple negative breast cancer.
The trial is still in the early stages and recruiting participants, so limited data is available.
View source →Trial Tests Combo Cancer Treatment
This trial is studying the safety of combining two anti-cancer drugs, CX-5461 and Trastuzumab Deruxtecan, for treating HER2-positive solid tumors and breast cancer. The trial is currently recruiting participants. It's too early to know if this combination will be effective.
Why it matters: This trial matters because it may lead to new treatment options for people with HER2-positive breast cancer and other solid tumors.
The trial is in its early stages and still recruiting participants, so limited data is available.
View source →Prostate Cancer Treatment Trial
This trial is studying a combination of treatments for castration-sensitive oligometastatic prostate cancer. The trial is currently active but not recruiting new participants. Researchers are exploring the effectiveness of these treatments together.
Why it matters: This trial matters because it may help find new ways to treat prostate cancer that has spread to a limited number of areas in the body.
The trial is in an early stage and not recruiting new participants, so limited data is available.
View source →Breast Cancer Prevention Trial
This trial is studying whether acolbifene or low-dose tamoxifen can prevent breast cancer in premenopausal women at high risk. The trial is currently recruiting participants. It's too early to know if either treatment will be effective.
Why it matters: This trial matters because it may help find new ways to prevent breast cancer in women who are at high risk of developing the disease.
The trial is in its early stages and is still recruiting participants, so limited data is available.
View source →Combining Treatments for Lung Cancer
Researchers studied combining cetuximab with KRAS G12C inhibitors in lung cancer cells. They found that this combination enhanced the effect of one inhibitor, fulzerasib, in certain cells. The combination also changed the expression of various proteins in these cells.
Why it matters: This finding matters because it could help tailor treatments for patients with a specific type of lung cancer.
This is an early, preclinical study using cell lines and animal models, and its results may not translate to humans.
View source →Lung Cancer Immunotherapy Trial
This trial is studying if immunotherapy helps people with early-stage non-small cell lung cancer after standard treatment. The trial is currently recruiting participants. It's not yet known if this treatment will be effective.
Why it matters: This trial matters because it may help find new ways to treat lung cancer and prevent it from coming back.
The trial is currently recruiting and no results are available yet.
View source →Lung Cancer Treatment Trial
This trial is studying the addition of an anti-cancer drug, TRC102, to the usual chemotherapy treatment during radiation therapy for stage III non-squamous non-small cell lung cancer. The trial is currently recruiting participants. The goal is to see if this new combination is effective.
Why it matters: This trial matters because it may help find new and potentially more effective treatments for stage III non-squamous non-small cell lung cancer.
The trial is currently recruiting and is in an early stage, so limited data is available.
View source →Lung Cancer Treatment Study
This trial is studying a new combination of treatments for patients with a specific type of lung cancer. The trial is currently recruiting participants. It's too early to know if this treatment will be effective.
Why it matters: This trial matters because it may help find a new treatment option for patients with EGFR-mutant lung cancer.
The trial is currently recruiting and no results are available yet.
View source →Nivolumab and Ipilimumab Trial
This trial is studying the use of nivolumab and ipilimumab in treating patients with rare tumors. The trial is currently active but not recruiting new patients. Researchers are collecting data to see how well these treatments work.
Why it matters: This trial matters because it may help find new treatments for people with rare types of cancer.
The trial is currently not recruiting new patients and is in an early stage of research.
View source →Radium Therapy for Advanced Breast Cancer
This trial is studying the addition of radium therapy to chemotherapy for advanced breast cancer that has spread to the bones. The trial is currently active but not recruiting new participants. Researchers are exploring whether this combination is effective.
Why it matters: This trial matters because it may help find new ways to treat advanced breast cancer that has spread to the bones.
The trial is currently not recruiting new participants and is in an early stage with limited data.
View source →Propofol Enhances Cancer Treatment
Researchers studied how propofol affects non-small cell lung cancer cells. They found that propofol makes these cells more sensitive to a common chemotherapy drug. This happened through a process that involves modifying a protein called PARP-1.
Why it matters: This finding matters because it could help scientists understand how to make chemotherapy more effective for patients with non-small cell lung cancer.
This is an early study using animal models and lab experiments, and more research is needed to confirm these results in humans.
View source →Trial Tests New Combo for Advanced Breast Cancer
This trial is studying a new combination of treatments for advanced triple-negative breast cancer. It's adding an anti-cancer drug called ZEN-3694 and a PD-1 inhibitor to standard chemotherapy. The trial is currently recruiting participants.
Why it matters: This trial matters because it may help find new and more effective treatments for advanced triple-negative breast cancer.
The trial is in its early stage and currently recruiting participants, so limited data is available.
View source →Lung Cancer Treatment Trial
This trial is studying the addition of an antibody to standard chemoradiation for patients with stage III non-small cell lung cancer. The trial is currently active but not recruiting new patients. Researchers are testing if this new approach is effective.
Why it matters: This trial matters because it may lead to a new treatment option for patients with unresectable stage III non-small cell lung cancer.
The trial is not recruiting new patients and no results have been reported yet.
View source →ONC201 Trial for Colorectal Cancer
This trial is studying the safety and potential preventive effects of ONC201 on colorectal cancer. The trial is currently recruiting participants with certain conditions, including colorectal adenomatous polyp and familial adenomatous polyposis. Researchers will collect data through procedures like biopsy and colonoscopy.
Why it matters: This trial matters because it may help researchers understand how to prevent colorectal cancer in people with certain conditions.
The trial is in its early stage and currently recruiting participants, so limited data is available.
View source →